Genfit S.A. (GNFTF)

OTC • Market Data in USD, Fundamentals in EUR

$3.72

$0.00

0.00%

Last Update: 2 Sept 2025, 00:00

$185.24M

Market Cap

0.00

P/E Ratio (TTM)

—

Forward Dividend Yield

$3.28 - $5.55

52 Week Range

GNFTF Stock Price Chart

Explore Genfit S.A. interactive price chart. Choose custom timeframes to analyze GNFTF price movements and trends.

GNFTF Company Profile

Discover essential business fundamentals and corporate details for Genfit S.A. (GNFTF) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

27 Jan 2014

Employees

180.00

Website

https://www.genfit.com

CEO

M. Pascal Prigent

Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

GNFTF Financial Timeline

Browse a chronological timeline of Genfit S.A. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 22 Apr 2026

Upcoming earnings on 22 Sept 2025

Earnings released on 22 May 2025

Earnings released on 24 Apr 2025

EPS came in at -$0.58 falling short of the estimated -$0.24 by -138.29%, while revenue for the quarter reached $10.04M , missing expectations by -92.44%.

Earnings released on 7 Nov 2024

Earnings released on 19 Sept 2024

EPS came in at $0.50 surpassing the estimated $0.33 by +51.20%, while revenue for the quarter reached $61.10M , beating expectations by +860.53%.

Earnings released on 14 May 2024

Earnings released on 4 Apr 2024

EPS came in at -$0.16 falling short of the estimated $1.35 by -111.98%, while revenue for the quarter reached $17.08M , missing expectations by -79.58%.

Earnings released on 30 Dec 2023

EPS came in at -$0.15 , while revenue for the quarter reached $28.57M .

Earnings released on 20 Sept 2023

EPS came in at -$0.42 falling short of the estimated -$0.39 by -7.58%, while revenue for the quarter reached $11.48M , missing expectations by -26.49%.

Earnings released on 13 Apr 2023

EPS came in at -$0.27 surpassing the estimated -$1.08 by +75.17%, while revenue for the quarter reached $6.10M , missing expectations by -58.02%.

Earnings released on 31 Dec 2022

EPS came in at -$0.12 , while revenue for the quarter reached $20.20M .

Earnings released on 28 Sept 2022

EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.97%, while revenue for the quarter reached $8.79M , beating expectations by +299.40%.

Earnings released on 11 May 2022

EPS came in at $1.46 surpassing the estimated -$0.90 by +262.59%, while revenue for the quarter reached $93.40M , beating expectations by +2.01K%.

Earnings released on 28 Feb 2022

EPS came in at $1.02 surpassing the estimated -$0.79 by +229.11%, while revenue for the quarter reached $80.06M .

Earnings released on 24 Jan 2022

Earnings released on 29 Sept 2021

EPS came in at $0.19 surpassing the estimated -$1.20 by +115.86%, while revenue for the quarter reached $11.00K , missing expectations by -99.58%.

Earnings released on 12 May 2021

Earnings released on 1 Apr 2021

EPS came in at -$1.24 falling short of the estimated -$0.86 by -44.48%, while revenue for the quarter reached $643.00K , missing expectations by -88.40%.

Earnings released on 16 Nov 2020

Earnings released on 30 Sept 2020

EPS came in at -$1.37 falling short of the estimated -$0.94 by -45.31%, while revenue for the quarter reached $122.00K , missing expectations by -96.95%.

GNFTF Stock Performance

Access detailed GNFTF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.